CLRB vs. INCR, ANVS, PDSB, EBS, IOBT, RNAC, ANIX, ADAG, BRNS, and IMUX
Should you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include InterCure (INCR), Annovis Bio (ANVS), PDS Biotechnology (PDSB), Emergent BioSolutions (EBS), IO Biotech (IOBT), Cartesian Therapeutics (RNAC), Anixa Biosciences (ANIX), Adagene (ADAG), Barinthus Biotherapeutics (BRNS), and Immunic (IMUX). These companies are all part of the "pharmaceutical preparations" industry.
InterCure (NASDAQ:INCR) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, community ranking, dividends, media sentiment, valuation and earnings.
InterCure has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.
InterCure has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cellectar Biosciences had 1 more articles in the media than InterCure. MarketBeat recorded 2 mentions for Cellectar Biosciences and 1 mentions for InterCure. Cellectar Biosciences' average media sentiment score of 0.00 equaled InterCure'saverage media sentiment score.
Cellectar Biosciences has a consensus target price of $20.00, indicating a potential upside of 553.59%. Given InterCure's higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than InterCure.
Cellectar Biosciences' return on equity of 0.00% beat InterCure's return on equity.
Cellectar Biosciences received 237 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 56.07% of users gave Cellectar Biosciences an outperform vote.
8.3% of InterCure shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 0.2% of InterCure shares are held by insiders. Comparatively, 4.6% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
InterCure beats Cellectar Biosciences on 8 of the 14 factors compared between the two stocks.
Get Cellectar Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectar Biosciences Competitors List
Related Companies and Tools
